Open Access
J Extra Corpor Technol
Volume 53, Number 2, June 2021
Page(s) 97 - 124
Published online 15 June 2021
  1. Klein AA, Collier TJ, Brar MS, et al. . The incidence and importance of anaemia in patients undergoing cardiac surgery in the UK – the first association of cardiothoracic anaesthetists national audit. Anaesthesia. 2016;71:627–35. [CrossRef] [PubMed] [Google Scholar]
  2. Munoz M, Laso-Morales MJ, Gomez-Ramirez S, et al. . Pre-operative haemoglobin levels and iron status in a large multicentre cohort of patients undergoing major elective surgery. Anaesthesia. 2017;72:826–34. [CrossRef] [PubMed] [Google Scholar]
  3. von Heymann C, Kaufner L, Sander M, et al. . Does the severity of preoperative anemia or blood transfusion have a stronger impact on long-term survival after cardiac surgery? J Thorac Cardiovasc Surg 2016;152:1412–20. [CrossRef] [PubMed] [Google Scholar]
  4. Hung M, Besser M, Sharples LD, et al. . The prevalence and association with transfusion, intensive care unit stay and mortality of pre-operative anaemia in a cohort of cardiac surgery patients. Anaesthesia. 2011;66:812–8. [CrossRef] [PubMed] [Google Scholar]
  5. Spiegelstein D, Holmes SD, Pritchard G, et al. . Preoperative hematocrit as a predictor of perioperative morbidities following nonemergent coronary artery bypass surgery. J Card Surg. 2015;30:20–6. [CrossRef] [PubMed] [Google Scholar]
  6. Engoren M, Schwann TA, Habib RH, et al. . The independent effects of anemia and transfusion on mortality after coronary artery bypass. Ann Thorac Surg. 2014;97:514–20. [CrossRef] [PubMed] [Google Scholar]
  7. Oprea AD, Del Rio JM, Cooter M, et al. . Pre- and postoperative anemia, acute kidney injury, and mortality after coronary artery bypass grafting surgery: A retrospective observational study. Can J Anaesth. 2018;65:46–59. [CrossRef] [PubMed] [Google Scholar]
  8. Dai L, Mick SL, McCrae KR, et al. . Preoperative anemia in cardiac operation: Does hemoglobin tell the whole story? Ann Thorac Surg 2018;105:100–7. [CrossRef] [PubMed] [Google Scholar]
  9. Peters F, Eveslage M, Gallitz I, et al. . Post-operative iron carboxymaltose may have an effect on haemoglobin levels in cardiothoracic surgical patients on the ICU - an observational pilot study about anaemia treatment with intravenous iron. Transfus Med Hemother. 2018;45:42–6. [CrossRef] [PubMed] [Google Scholar]
  10. Padmanabhan H, Siau K, Nevill AM, et al. . Intravenous iron does not effectively correct preoperative anaemia in cardiac surgery: A pilot randomized controlled trial. Interact Cardiovasc Thorac Surg. 2019;28:447–54. [CrossRef] [PubMed] [Google Scholar]
  11. Yoo YC, Shim JK, Kim JC, et al. . Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology. 2011;115:929–37. [CrossRef] [PubMed] [Google Scholar]
  12. Cladellas M, Farre N, Comin-Colet J, et al. . Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement. Am J Cardiol. 2012;110:1021–6. [CrossRef] [PubMed] [Google Scholar]
  13. Kei T, Mistry N, Curley G, et al. . Efficacy and safety of erythropoietin and iron therapy to reduce red blood cell transfusion in surgical patients: A systematic review and meta-analysis. Can J Anaesth . 2019;66:716–31. [CrossRef] [PubMed] [Google Scholar]
  14. Cho BC, Serini J, Zorrilla-Vaca A, et al. . Impact of preoperative erythropoietin on allogeneic blood transfusions in surgical patients: Results from a systematic review and meta-analysis. Anesth Analg. 2019;128:981–92. [CrossRef] [PubMed] [Google Scholar]
  15. Song YR, Lee T, You SJ, et al. . Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: A pilot study. Am J Nephrol. 2009;30:253–60. [CrossRef] [PubMed] [Google Scholar]
  16. Tasanarong A, Duangchana S, Sumransurp S, et al. . Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocalin in patients undergoing cardiac surgery: A randomized, double-blind controlled trial. BMC Nephrol. 2013;14:136. [CrossRef] [PubMed] [Google Scholar]
  17. Oh SW, Chin HJ, Chae DW, et al. . Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting. J Korean Med Sci. 2012;27:506–11. [CrossRef] [PubMed] [Google Scholar]
  18. Fisher JW. Pharmacologic modulation of erythropoietin production. Annu Rev Pharmacol Toxicol. 1988;28:101–22. [CrossRef] [PubMed] [Google Scholar]
  19. Beattie WS, Wijeysundera DN, Karkouti K, et al. . Acute surgical anemia influences the cardioprotective effects of beta-blockade: A single-center, propensity-matched cohort study. Anesthesiology . 2010;112:25–33. [CrossRef] [PubMed] [Google Scholar]
  20. Means RT Jr. Clinical application of recombinant erythropoietin in the anemia of chronic disease. Hematol Oncol Clin North Am. 1994;8:933–44. [CrossRef] [PubMed] [Google Scholar]
  21. Weltert L, Rondinelli B, Bello R, et al. . A single dose of erythropoietin reduces perioperative transfusions in cardiac surgery: Results of a prospective single-blind randomized controlled trial. Transfusion . 2015;55:1644–54. [CrossRef] [PubMed] [Google Scholar]
  22. Weltert L, D’Alessandro S, Nardella S, et al. Preoperative very short-term, high-dose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: A randomized blind controlled study. J Thorac Cardiovasc Surg . 2010;139:621–6; [discussion: 626-627]. [CrossRef] [PubMed] [Google Scholar]
  23. Penny-Dimri JC, Cochrane AD, Perry LA, et al. . Characterising the role of perioperative erythropoietin for preventing acute kidney injury after cardiac surgery: Systematic review and meta-analysis. Heart Lung Circ . 2016;25:1067–76. [CrossRef] [PubMed] [Google Scholar]
  24. Spahn DR, Schoenrath F, Spahn GH, et al. . Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: A prospective randomised trial. Lancet. 2019;393:2201–12. [CrossRef] [PubMed] [Google Scholar]
  25. Tezcan B, Bolukbasi D, Saylan A, et al. . Effect of dilutional anemia that can be treated with only one unit of red blood cell transfusion on tissue oxygenation in cardiac surgery patients. Turk J Med Sci. 2019;49:1102–8. [CrossRef] [PubMed] [Google Scholar]
  26. Ferraris V, Saha SP, Vyas KS, et al. . Blood conservation – balancing risks and benefits. In: Frank SM, Waters JH, eds. Patient Blood Management: Multidisciplinary Approaches to Optimizing Care. Bethesda, MD: aABB Press; 2016:345–70. [Google Scholar]
  27. Ferraris VA, Hochstetler M, Martin JT, et al. . Blood transfusion and adverse surgical outcomes: The good and the bad. Surgery. 2015;158:608–17. [CrossRef] [PubMed] [Google Scholar]
  28. Padmanabhan H, Siau K, Curtis J, et al. . Preoperative anemia and outcomes in cardiovascular surgery: Systematic review and meta-analysis. Ann Thorac Surg. 2019;108:1840–8. [CrossRef] [PubMed] [Google Scholar]
  29. Vlot EA, Verwijmeren L, van de Garde EMW, et al. . Intra-operative red blood cell transfusion and mortality after cardiac surgery. BMC Anesthesiol. 2019;19:65. [CrossRef] [PubMed] [Google Scholar]
  30. Jabagi H, Boodhwani M, Tran DT, et al. . The effect of preoperative anemia on patients undergoing cardiac surgery: A propensity-matched analysis. Semin Thorac Cardiovasc Surg. 2019;31:157–63. [CrossRef] [PubMed] [Google Scholar]
  31. Yanagawa B, Rocha RV, Mazine A, et al. . Hemoglobin optimization for coronary bypass: A 10-year Canadian multicenter experience. Ann Thorac Surg. 2019;107:711–7. [CrossRef] [PubMed] [Google Scholar]
  32. Ayoub K, Marji M, Ogunbayo G, et al. . Impact of chronic thrombocytopenia on in-hospital outcomes after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11:1862–8. [CrossRef] [PubMed] [Google Scholar]
  33. Sapiano MRP, Jones JM, Savinkina AA, et al. . Supplemental findings of the 2017 national blood collection and utilization survey. Transfusion. 2020;60(Suppl 2):S17–S37. [PubMed] [Google Scholar]
  34. Vassallo R, Goldman M, Germain M, et al. . Preoperative autologous blood donation: Waning indications in an era of improved blood safety. Transfus Med Rev. 2015;29:268–75. [CrossRef] [PubMed] [Google Scholar]
  35. Martin K, Keller E, Gertler R, et al. . Efficiency and safety of preoperative autologous blood donation in cardiac surgery: A matched-pair analysis in 432 patients. Eur J Cardio Thorac Surg. 2010;37:1396–401. [CrossRef] [Google Scholar]
  36. Lim MH, Je HG, Ju MH, et al. . Effects of preoperative autologous blood donation in patients undergoing minimally invasive cardiac surgery. Korean J Thorac Cardiovasc Surg. 2019;52:385–91. [CrossRef] [PubMed] [Google Scholar]
  37. Zimmermann E, Zhu R, Ogami T, et al. . Intraoperative autologous blood donation leads to fewer transfusions in cardiac surgery. Ann Thorac Surg. 2019;108:1738–44. [CrossRef] [PubMed] [Google Scholar]
  38. Schloendorff V. Society of New York Hospital. New York, NY: Court of Appeals; 1914:92. [Google Scholar]
  39. Cobbs v. Grant. 505: Supreme Court of California. 1972: 229. [Google Scholar]
  40. Perlin TM. Clinical Medical Ethics: Cases in Practice. Boston, MA: Little Brown & Co.; 1992. [Google Scholar]
  41. The American College of Surgeons (ACS) Committee on Ethics. Statement on Recommendations for Surgeons Caring for Patients Who Are Jehovah’s Witnesses. Chicago, IL: American College of Surgeons; 2018. [Google Scholar]
  42. Bodnaruk ZM, Wong CJ, Thomas MJ. Meeting the clinical challenge of care for Jehovah’s Witnesses. Transfus Med Rev. 2004;18:105–16. [CrossRef] [PubMed] [Google Scholar]
  43. Rogers DM, Crookston KP. The approach to the patient who refuses blood transfusion. Transfusion. 2006;46:1471–7. [CrossRef] [PubMed] [Google Scholar]
  44. Stowell CP, Sazama K. Informed Consent in Blood Transfusion and Cellular Therapies: Patients, Donors, and Research Subjects. Bethesda, MD: aABB Press; 2007. [Google Scholar]
  45. Barnes GD, Lucas E, Alexander GC, et al. . National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128:1300–5.e2. [CrossRef] [PubMed] [Google Scholar]
  46. Zhu J, Alexander GC, Nazarian S, et al. . Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017. Pharmacotherapy. 2018;38:907–20. [CrossRef] [PubMed] [Google Scholar]
  47. Connolly SJ, Ezekowitz MD, Yusuf S, et al. . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. [CrossRef] [PubMed] [Google Scholar]
  48. Patel MR, Mahaffey KW, Garg J, et al. . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. [CrossRef] [PubMed] [Google Scholar]
  49. Granger CB, Alexander JH, McMurray JJ, et al. . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. [CrossRef] [PubMed] [Google Scholar]
  50. Giugliano RP, Ruff CT, Braunwald E, et al. . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104. [CrossRef] [PubMed] [Google Scholar]
  51. Douxfils J, Ageno W, Samama CM, et al. . Laboratory testing in patients treated with direct oral anticoagulants: A practical guide for clinicians. J Thromb Haemost. 2018;16:209–19. [CrossRef] [PubMed] [Google Scholar]
  52. Raval AN, Cigarroa JE, Chung MK, et al. . Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: A scientific statement from the American heart association. Circulation. 2017;135:e604–33. [CrossRef] [PubMed] [Google Scholar]
  53. Gosselin RC, Adcock DM, Bates SM, et al. . International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2018;118:437–50. [CrossRef] [PubMed] [Google Scholar]
  54. Erdoes G, Martinez Lopez De Arroyabe B, Bolliger D, et al. . International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery. Anaesthesia. 2018;73:1535–45. [CrossRef] [PubMed] [Google Scholar]
  55. De Caterina R, Ageno W, Agnelli G, et al. . The non-vitamin K antagonist oral anticoagulants in heart disease: Section V-special situations. Thromb Haemost. 2019;119:14–38. [Google Scholar]
  56. Hassan K, Bayer N, Schlingloff F, et al. . Bleeding complications after use of novel oral anticoagulants in patients undergoing cardiac surgery. Ann Thorac Surg. 2018;105:702–8. [CrossRef] [PubMed] [Google Scholar]
  57. Yu PJ, Lin D, Catalano M, et al. . Impact of novel oral anticoagulants vs warfarin on effusions after coronary artery bypass grafting. J Card Surg. 2019;34:419–23. [CrossRef] [PubMed] [Google Scholar]
  58. Cuker A, Burnett A, Triller D, et al. . Reversal of direct oral anticoagulants: Guidance from the anticoagulation forum. Am J Hematol. 2019;94:697–709. [CrossRef] [PubMed] [Google Scholar]
  59. Ferraris VA, Brown JR, Despotis GJ, et al. . 2011 Update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91:944–82. [CrossRef] [PubMed] [Google Scholar]
  60. Sarode R, Milling TJ Jr, Refaai MA, et al. . Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: A randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234–43. [CrossRef] [PubMed] [Google Scholar]
  61. Cappabianca G, Mariscalco G, Biancari F, et al. . Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Crit Care. 2016;20:5. [CrossRef] [PubMed] [Google Scholar]
  62. Roman M, Biancari F, Ahmed AB, et al. . Prothrombin complex concentrate in cardiac surgery: A systematic review and meta-analysis. Ann Thorac Surg. 2019;107:1275–83. [CrossRef] [PubMed] [Google Scholar]
  63. Bassand JP, Hamm CW, Ardissino D, et al. . Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598–660. [Google Scholar]
  64. Anderson JL, Adams CD, Antman EM, et al. . ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American heart association Task Force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable Angina/non-ST-elevation myocardial infarction) developed in collaboration with the American College of emergency physicians, the society for cardiovascular Angiography and interventions, and the society of thoracic surgeons endorsed by the American association of cardiovascular and pulmonary Rehabilitation and the society for academic emergency medicine. J Am Coll Cardiol. 2007;50:e1–e157. [CrossRef] [PubMed] [Google Scholar]
  65. Mehta SR, Yusuf S, Peters RJ, et al. . Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet. 2001;358:527–33. [CrossRef] [PubMed] [Google Scholar]
  66. Yusuf S, Zhao F, Mehta SR, et al. . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502. [CrossRef] [PubMed] [Google Scholar]
  67. Steinhubl SR, Berger PB, Mann JT 3rd, et al. . Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. J Am Med Assoc. 2002;288:2411–20. [CrossRef] [PubMed] [Google Scholar]
  68. Fox KA, Mehta SR, Peters R, et al. . Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: The clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. Circulation. 2004;110:1202–8. [CrossRef] [PubMed] [Google Scholar]
  69. Held C, Asenblad N, Bassand JP, et al. . Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: Results from the PLATO (platelet inhibition and patient outcomes) trial. J Am Coll Cardiol. 2011;57:672–84. [CrossRef] [PubMed] [Google Scholar]
  70. Smith PK, Goodnough LT, Levy JH, et al. . Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: Risk-adjusted retrospective data analysis. J Am Coll Cardiol. 2012;60:388–96. [CrossRef] [PubMed] [Google Scholar]
  71. Hansson EC, Jideus L, Aberg B, et al. . Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: A nationwide study. Eur Heart J. 2016;37:189–97. [CrossRef] [PubMed] [Google Scholar]
  72. Tomsic A, Schotborgh MA, Manshanden JS, et al. . Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment. Eur J Cardio Thorac Surg. 2016;50:849–56. [CrossRef] [PubMed] [Google Scholar]
  73. Pickard AS, Becker RC, Schumock GT, et al. . Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting. Pharmacotherapy. 2008;28:376–92. [CrossRef] [PubMed] [Google Scholar]
  74. Purkayastha S, Athanasiou T, Malinovski V, et al. . Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis. Heart. 2006;92:531–2. [Google Scholar]
  75. Kushner FG, Hand M, Smith SC Jr, et al. . 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54:2205–41. [CrossRef] [PubMed] [Google Scholar]
  76. Kolh P, Windecker S, Alfonso F, et al. . 2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on myocardial revascularization of the European society of Cardiology (ESC) and the European association for Cardio-thoracic surgery (EACTS). Developed with the special contribution of the European association of percutaneous cardiovascular interventions (EAPCI). Eur J Cardio Thorac Surg. 2014;46:517–92. [CrossRef] [PubMed] [Google Scholar]
  77. Mishra PK, Thekkudan J, Sahajanandan R, et al. . The role of point-of-care assessment of platelet function in predicting postoperative bleeding and transfusion requirements after coronary artery bypass grafting. Ann Card Anaesth. 2015;18:45–51. [CrossRef] [PubMed] [Google Scholar]
  78. Rahe-Meyer N, Winterhalter M, Boden A, et al. . Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol Scand. 2009;53:168–75. [CrossRef] [PubMed] [Google Scholar]
  79. Wallentin L. P2Y(12) inhibitors: Differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009;30:1964–77. [CrossRef] [PubMed] [Google Scholar]
  80. Cao C, Indraratna P, Ang SC, et al. . Should clopidogrel be discontinued before coronary artery bypass grafting for patients with acute coronary syndrome? A systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2014;148:3092–8. [CrossRef] [PubMed] [Google Scholar]
  81. Gurbel PA, Bliden KP, Butler K, et al. . Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study. Circulation. 2009;120:2577–85. [CrossRef] [PubMed] [Google Scholar]
  82. Kremke M, Gissel MS, Jensen MJ, et al. . The association between a three-day ticagrelor discontinuation and perioperative bleeding complications. Eur J Cardio Thorac Surg. 2019;55:714–20. [CrossRef] [PubMed] [Google Scholar]
  83. Valgimigli M, Bueno H, Byrne RA, et al. . 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardio Thorac Surg. 2018;53:34–78. [CrossRef] [PubMed] [Google Scholar]
  84. Ouattara A, Bouzguenda H, Le Manach Y, et al. . Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin. Eur Heart J. 2007;28:1025–32. [CrossRef] [PubMed] [Google Scholar]
  85. Amour J, Garnier M, Szymezak J, et al. . Prospective observational study of the effect of dual antiplatelet therapy with tranexamic acid treatment on platelet function and bleeding after cardiac surgery. Br J Anaesth. 2016;117:749–57. [CrossRef] [PubMed] [Google Scholar]
  86. Myles PS, Smith JA, Forbes A, et al. . Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med. 2017;376:136–48. [CrossRef] [PubMed] [Google Scholar]
  87. Taghaddomi RJ, Mirzaee A, Attar AS, et al. . Tranexamic acid reduces blood loss in off-pump coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 2009;23:312–5. [CrossRef] [PubMed] [Google Scholar]
  88. Esfandiari BR, Bistgani MM, Kabiri M. Low dose tranexamic acid effect on post-coronary artery bypass grafting bleeding. Asian Cardiovasc Thorac Ann. 2013;21:669–74. [CrossRef] [PubMed] [Google Scholar]
  89. Wang G, Xie G, Jiang T, et al. . Tranexamic acid reduces blood loss after off-pump coronary surgery: A prospective, randomized, double-blind, placebo-controlled study. Anesth Analg. 2012;115:239–43. [CrossRef] [PubMed] [Google Scholar]
  90. Raghunathan K, Connelly NR, Kanter GJ. Epsilon-Aminocaproic acid and clinical value in cardiac anesthesia. J Cardiothorac Vasc Anesth. 2011;25:16–9. [CrossRef] [PubMed] [Google Scholar]
  91. Alizadeh Ghavidel A, Totonchi Z, Chitsazan M, et al. . Safety and efficacy of caproamin fides and tranexamic acid versus placebo in patients undergoing coronary artery revascularization. J Cardiovasc Thorac Res. 2014;6:197–202. [CrossRef] [PubMed] [Google Scholar]
  92. Choudhuri P, Biswas BK. Intraoperative use of epsilon amino caproic acid and tranexamic acid in surgeries performed under cardiopulmonary bypass: A comparative study to assess their impact on reopening due to postoperative bleeding. Ethiop J Health Sci. 2015;25:273–8. [CrossRef] [PubMed] [Google Scholar]
  93. Keyl C, Uhl R, Beyersdorf F, et al. . High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardio Thorac Surg. 2011;39:e114–21. [CrossRef] [Google Scholar]
  94. Martin K, Knorr J, Breuer T, et al. . Seizures after open heart surgery: Comparison of epsilon-aminocaproic acid and tranexamic acid. J Cardiothorac Vasc Anesth. 2011;25:20–5. [CrossRef] [PubMed] [Google Scholar]
  95. Fergusson DA, Hébert PC, Mazer CD, et al. . A comparison of aprotinin and lysine analogues in high-risk cardiac surgery [published correction appears in N Engl J Med. 2008;358:2319–31. [CrossRef] [PubMed] [Google Scholar]
  96. Hutton B, Joseph L, Fergusson D, et al. . Risks of harms using antifibrinolytics in cardiac surgery: Systematic review and network meta-analysis of randomised and observational studies. BMJ. 2012;345:e5798. [CrossRef] [PubMed] [Google Scholar]
  97. Henry D, Carless P, Fergusson D, et al. . The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: A meta-analysis. CMAJ. 2009;180:183–93. [CrossRef] [PubMed] [Google Scholar]
  98. McIlroy DR, Myles PS, Phillips LE, et al. . Antifibrinolytics in cardiac surgical patients receiving aspirin: A systematic review and meta-analysis. Br J Anaesth. 2009;102:168–78. [CrossRef] [PubMed] [Google Scholar]
  99. Ngaage DL, Bland JM. Lessons from aprotinin: Is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies. Eur J Cardio Thorac Surg. 2010;37:1375–83. [CrossRef] [Google Scholar]
  100. Howell N, Senanayake E, Freemantle N, et al. . Putting the record straight on aprotinin as safe and effective: Results from a mixed treatment meta-analysis of trials of aprotinin. J Thorac Cardiovasc Surg. 2013;145:234–40. [CrossRef] [PubMed] [Google Scholar]
  101. Mansouri M, Attary M, Bagheri K, et al. . Comparative evaluation of the effects of tranexamic acid and low-dose aprotinin on post-valvular heart surgery bleeding and allogenic transfusion. Interact Cardiovasc Thorac Surg. 2012;15:23–7. [CrossRef] [PubMed] [Google Scholar]
  102. Nejad MHG, Baharestani B, Esfandiari R, et al. . Evaluation and comparison of using low-dose aprotinin and tranexamic acid in CABG: A double blind randomized clinical trial. J Tehran Heart Cent. 2012;7:15–8. [PubMed] [Google Scholar]
  103. Riddell RE, Buth KJ, Sullivan JA. The risks associated with aprotinin use: A retrospective study of cardiac cases in Nova Scotia. Can J Anaesth. 2013;60:16–23. [CrossRef] [PubMed] [Google Scholar]
  104. Deloge E, Amour J, Provenchère S, et al. . Aprotinin vs. tranexamic acid in isolated coronary artery bypass surgery: A multicentre observational study. Eur J Anaesthesiol. 2017;34:280–7. [CrossRef] [PubMed] [Google Scholar]
  105. Lewis KM, Li Q, Jones DS, et al. . Development and validation of an intraoperative bleeding severity scale for use in clinical studies of hemostatic agents. Surgery. 2017;161:771–81. [CrossRef] [PubMed] [Google Scholar]
  106. Myles PS. Meaningful outcome measures in cardiac surgery. J Extra Corpor Technol. 2014;46:23–7. [PubMed] [Google Scholar]
  107. Genereux P, Cohen DJ, Williams MR, et al. . Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacement: Insights from the PARTNER I trial (Placement of aortic transcatheter valve). J Am Coll Cardiol. 2014;63:1100–9. [CrossRef] [PubMed] [Google Scholar]
  108. Kirmani BH, Jones SG, Malaisrie SC, et al. . Limited versus full sternotomy for aortic valve replacement. Cochrane Database Syst Rev. 2017;4:CD011793. [PubMed] [Google Scholar]
  109. Sundermann SH, Sromicki J, Rodriguez Cetina Biefer H, et al. . Mitral valve surgery: Right lateral minithoracotomy or sternotomy? A systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2014;148:1989–95.e4. [CrossRef] [PubMed] [Google Scholar]
  110. Shroyer AL, Grover FL, Hattler B, et al. . On-pump versus off-pump coronary-artery bypass surgery. N Engl J Med. 2009;361:1827–37. [CrossRef] [PubMed] [Google Scholar]
  111. Lamy A, Devereaux PJ, Prabhakaran D, et al. . Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med. 2012;366:1489–97. [CrossRef] [PubMed] [Google Scholar]
  112. Lamy A, Devereaux PJ, Prabhakaran D, et al. . Five-year outcomes after off-pump or on-pump coronary-artery bypass grafting. N Engl J Med. 2016;375:2359–68. [CrossRef] [PubMed] [Google Scholar]
  113. Shroyer AL, Hattler B, Grover FL. Five-year outcomes after on-pump and off-pump coronary-artery bypass. N Engl J Med. 2017;377:1898–9. [Google Scholar]
  114. Shore-Lesserson L, Baker RA, Ferraris VA, et al. . The society of thoracic surgeons, the society of cardiovascular Anesthesiologists, and the American society of ExtraCorporeal technology: Clinical practice guidelines—anticoagulation during cardiopulmonary bypass. Ann Thorac Surg. 2018;105:650–62. [CrossRef] [PubMed] [Google Scholar]
  115. Ak K, Isbir CS, Tetik S, et al. . Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: A prospective randomized study. J Card Surg. 2009;24:404–10. [CrossRef] [PubMed] [Google Scholar]
  116. Shore-Lesserson L, Manspeizer HE, DePerio M, et al. . Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg. 1999;88:312–9. [CrossRef] [PubMed] [Google Scholar]
  117. Weber CF, Gorlinger K, Meininger D, et al. . Point-of-care testing: A prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology. 2012;117:531–47. [CrossRef] [PubMed] [Google Scholar]
  118. Deppe AC, Weber C, Zimmermann J, et al. . Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: A meta-analysis of 8332 patients. J Surg Res. 2016;203:424–33. [CrossRef] [PubMed] [Google Scholar]
  119. Haas T, Fries D, Tanaka KA, et al. . Usefulness of standard plasma coagulation tests in the management of perioperative coagulopathic bleeding: Is there any evidence? Br J Anaesth. 2015;114:217–24. [CrossRef] [PubMed] [Google Scholar]
  120. Toulon P, Ozier Y, Ankri A, et al. . Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery. A multicenter study. Thromb Haemost. 2009;101:394–401. [CrossRef] [PubMed] [Google Scholar]
  121. Karkouti K, McCluskey SA, Callum J, et al. . Evaluation of a novel transfusion algorithm employing point-of-care coagulation assays in cardiac surgery: A retrospective cohort study with interrupted time-series analysis. Anesthesiology. 2015;122:560–70. [CrossRef] [PubMed] [Google Scholar]
  122. Karkouti K, Callum J, Wijeysundera DN, et al. . Point-of-care hemostatic testing in cardiac surgery: A stepped-wedge clustered randomized controlled trial. Circulation. 2016;134:1152–62. [CrossRef] [PubMed] [Google Scholar]
  123. Afshari A, Wikkelso A, Brok J, et al. . Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev. 2011:CD007871. [PubMed] [Google Scholar]
  124. Dirkmann D, Gorlinger K, Dusse F, et al. . Early thromboelastometric variables reliably predict maximum clot firmness in patients undergoing cardiac surgery: A step towards earlier decision making. Acta Anaesthesiol Scand. 2013;57:594–603. [CrossRef] [PubMed] [Google Scholar]
  125. Corredor C, Wasowicz M, Karkouti K, et al. . The role of point-of-care platelet function testing in predicting postoperative bleeding following cardiac surgery: A systematic review and meta-analysis. Anaesthesia. 2015;70:715–31. [CrossRef] [PubMed] [Google Scholar]
  126. Lodewyks C, Heinrichs J, Grocott HP, et al. . Point-of-care viscoelastic hemostatic testing in cardiac surgery patients: A systematic review and meta-analysis. Can J Anaesth. 2018;65:1333–47. [CrossRef] [PubMed] [Google Scholar]
  127. Groves DS, Winegar DA, Fernandez LG, et al. . Comparison of coagulation parameters in arterial and venous blood in cardiac surgery measured using the Quantra system. J Cardiothorac Vasc Anesth. 2019;33:976–84. [CrossRef] [PubMed] [Google Scholar]
  128. Zghaibe W, Scheuermann S, Munting K, et al. . Clinical utility of the Quantra((R)) point-of-care haemostasis analyser during urgent cardiac surgery. Anaesthesia. 2020;75:366–73. [CrossRef] [PubMed] [Google Scholar]
  129. Goldberg J, Paugh TA, Dickinson TA, et al. . Greater volume of acute normovolemic hemodilution may aid in reducing blood transfusions after cardiac surgery. Ann Thorac Surg. 2015;100:1581–7; discussion 1587. [CrossRef] [PubMed] [Google Scholar]
  130. Stammers AH, Mongero LB, Tesdahl E, et al. . The effectiveness of acute normolvolemic hemodilution and autologous prime on intraoperative blood management during cardiac surgery. Perfusion. 2017;32:454–65. [CrossRef] [PubMed] [Google Scholar]
  131. Zhou ZF, Jia XP, Sun K, et al. . Mild volume acute normovolemic hemodilution is associated with lower intraoperative transfusion and postoperative pulmonary infection in patients undergoing cardiac surgery -- a retrospective, propensity matching study. BMC Anesthesiol. 2017;17:13. [CrossRef] [PubMed] [Google Scholar]
  132. Barile L, Fominskiy E, Di Tomasso N, et al. . Acute normovolemic hemodilution reduces allogeneic red blood cell transfusion in cardiac surgery: A systematic review and meta-analysis of randomized trials. Anesth Analg. 2017;124:743–52. [CrossRef] [PubMed] [Google Scholar]
  133. Saczkowski R, Bernier PL, Tchervenkov CI, et al. . Retrograde autologous priming and allogeneic blood transfusions: A meta-analysis. Interact Cardiovasc Thorac Surg. 2009;8:373–6. [CrossRef] [PubMed] [Google Scholar]
  134. Hofmann B, Kaufmann C, Stiller M, et al. . Positive impact of retrograde autologous priming in adult patients undergoing cardiac surgery: A randomized clinical trial. J Cardiothorac Surg. 2018;13:50. [CrossRef] [PubMed] [Google Scholar]
  135. Cheng M, Li JQ, Wu TC, et al. . Short-term effects and safety analysis of retrograde autologous blood priming for cardiopulmonary bypass in patients with cardiac valve replacement surgery. Cell Biochem Biophys. 2015;73:441–6. [CrossRef] [PubMed] [Google Scholar]
  136. Sun BC, Dickinson TA, Tesdahl EA, et al. . The unintended consequences of over-reducing cardiopulmonary bypass circuit prime volume. Ann Thorac Surg. 2017;103:1842–8. [CrossRef] [PubMed] [Google Scholar]
  137. Dickinson TA, Wu X, Sturmer DL, et al. . Net prime volume is associated with increased odds of blood transfusion. J Extra Corpor Technol. 2019;51:195–200. [PubMed] [Google Scholar]
  138. Anastasiadis K, Murkin J, Antonitsis P, et al. . Use of minimal invasive extracorporeal circulation in cardiac surgery: Principles, definitions and potential benefits. A position paper from the minimal invasive Extra-Corporeal Technologies international Society (MiECTiS). Interact Cardiovasc Thorac Surg. 2016;22:647–62. [CrossRef] [PubMed] [Google Scholar]
  139. Harling L, Warren OJ, Martin A, et al. . Do miniaturized extracorporeal circuits confer significant clinical benefit without compromising safety? A meta-analysis of randomized controlled trials. ASAIO J. 2011;57:141–51. [CrossRef] [PubMed] [Google Scholar]
  140. Anastasiadis K, Antonitsis P, Haidich AB, et al. . Use of minimal extracorporeal circulation improves outcome after heart surgery; a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2013;164:158–69. [CrossRef] [PubMed] [Google Scholar]
  141. El-Essawi A, Hajek T, Skorpil J, et al. . Are minimized perfusion circuits the better heart lung machines? Final results of a prospective randomized multicentre study. Perfusion. 2011;26:470–8. [CrossRef] [PubMed] [Google Scholar]
  142. Anastasiadis K, Asteriou C, Antonitsis P, et al. . Enhanced recovery after elective coronary revascularization surgery with minimal versus conventional extracorporeal circulation: A prospective randomized study. J Cardiothorac Vasc Anesth. 2013;27:859–64. [CrossRef] [PubMed] [Google Scholar]
  143. Baumbach H, Rustenbach CJ, Ahad S, et al. . Minimally invasive extracorporeal bypass in minimally invasive heart valve operations: A prospective randomized trial. Ann Thorac Surg. 2016;102:93–100. [CrossRef] [PubMed] [Google Scholar]
  144. Hajjar LA, Vincent JL, Galas FR, et al. . Transfusion requirements after cardiac surgery: The TRACS randomized controlled trial. J Am Med Assoc. 2010;304:1559–67. [CrossRef] [PubMed] [Google Scholar]
  145. Murphy GJ, Pike K, Rogers CA, et al. . Liberal or restrictive transfusion after cardiac surgery [published correction appears in N Engl J Med. 2015;372:997–1008. [CrossRef] [PubMed] [Google Scholar]
  146. Koch CG, Sessler DI, Mascha EJ, et al. . A randomized clinical trial of red blood cell transfusion triggers in cardiac surgery. Ann Thorac Surg. 2017;104:1243–50. [CrossRef] [PubMed] [Google Scholar]
  147. Shehata N, Burns LA, Nathan H, et al. . A randomized controlled pilot study of adherence to transfusion strategies in cardiac surgery. Transfusion. 2012;52:91–9. [CrossRef] [PubMed] [Google Scholar]
  148. Mazer CD, Whitlock RP, Fergusson DA, et al. . Restrictive or liberal red-cell transfusion for cardiac surgery. N Engl J Med. 2017;377:2133–44. [CrossRef] [PubMed] [Google Scholar]
  149. Mueller MM, Van Remoortel H, Meybohm P, et al. . Patient blood management: Recommendations from the 2018 Frankfurt consensus conference. J Am Med Assoc. 2019;321:983–97. [CrossRef] [PubMed] [Google Scholar]
  150. Kheiri B, Abdalla A, Osman M, et al. . Restrictive versus liberal red blood cell transfusion for cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. J Thromb Thrombolysis. 2019;47:179–85. [CrossRef] [PubMed] [Google Scholar]
  151. Shehata N, Mistry N, da Costa BR, et al. . Restrictive compared with liberal red cell transfusion strategies in cardiac surgery: A meta-analysis. Eur Heart J. 2019;40:1081–8. [CrossRef] [PubMed] [Google Scholar]
  152. Chen QH, Wang HL, Liu L, et al. . Effects of restrictive red blood cell transfusion on the prognoses of adult patients undergoing cardiac surgery: A meta-analysis of randomized controlled trials. Crit Care. 2018;22:142. [CrossRef] [PubMed] [Google Scholar]
  153. Parke RL, McGuinness SP, Gilder E, et al. . Intravenous fluid use after cardiac surgery: A multicentre, prospective, observational study. Crit Care Resusc. 2014;16:164–9. [PubMed] [Google Scholar]
  154. Brummel-Ziedins K, Whelihan MF, Ziedins EG, et al. . The resuscitative fluid you choose may potentiate bleeding. J Trauma. 2006;61:1350–8. [CrossRef] [PubMed] [Google Scholar]
  155. Kiraly LN, Differding JA, Enomoto TM, et al. . Resuscitation with normal saline (NS) vs. lactated ringers (LR) modulates hypercoagulability and leads to increased blood loss in an uncontrolled hemorrhagic shock swine model. J Trauma. 2006;61:57–64; discussion 64–65. [CrossRef] [PubMed] [Google Scholar]
  156. Shaw AD, Bagshaw SM, Goldstein SL, et al. . Major complications, mortality, and resource utilization after open abdominal surgery: 0.9% saline compared to plasma-Lyte. Ann Surg. 2012;255:821–9. [CrossRef] [PubMed] [Google Scholar]
  157. Waters JH, Gottlieb A, Schoenwald P, et al. . Normal saline versus lactated Ringer’s solution for intraoperative fluid management in patients undergoing abdominal aortic aneurysm repair: An outcome study. Anesth Analg. 2001;93:817–22. [CrossRef] [PubMed] [Google Scholar]
  158. Zhou F, Cove ME, Peng ZY, et al. . Normal saline resuscitation worsens lactic acidosis in experimental sepsis. Crit Care. 2012;16:P253. [CrossRef] [Google Scholar]
  159. Reddy SK, Bailey MJ, Beasley RW, et al. . Effect of 0.9% saline or Plasma-Lyte 148 as crystalloid fluid therapy in the intensive care unit on blood product use and postoperative bleeding after cardiac surgery. J Cardiothorac Vasc Anesth. 2017;31:1630–8. [CrossRef] [PubMed] [Google Scholar]
  160. RobertsL, BlackhallK, AldersonP, et al. . Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev. 2011:CD001208. [Google Scholar]
  161. Wigmore GJ, Anstey JR, St John A, et al. . 20% human albumin solution fluid bolus administration therapy in patients after cardiac surgery (the HAS FLAIR study). J Cardiothorac Vasc Anesth. 2019;33:2920–7. [CrossRef] [PubMed] [Google Scholar]
  162. Skhirtladze K, Base EM, Lassnigg A, et al. . Comparison of the effects of albumin 5%, hydroxyethyl starch 130/0.4 6%, and Ringer’s lactate on blood loss and coagulation after cardiac surgery. Br J Anaesth. 2014;112:255–64. [CrossRef] [PubMed] [Google Scholar]
  163. Fink RJ, Young A, Yanez ND, et al. . Cohort study of albumin versus lactated Ringer’s for postoperative cardiac surgery fluid resuscitation in the intensive care unit. Pharmacotherapy. 2018;38:1241–9. [CrossRef] [PubMed] [Google Scholar]
  164. Rabin J, Meyenburg T, Lowery AV, et al. . Restricted albumin utilization is safe and cost effective in a cardiac surgery intensive care unit. Ann Thorac Surg. 2017;104:42–8. [CrossRef] [PubMed] [Google Scholar]
  165. Frenette AJ, Bouchard J, Bernier P, et al. . Albumin administration is associated with acute kidney injury in cardiac surgery: A propensity score analysis. Crit Care. 2014;18:602. [CrossRef] [PubMed] [Google Scholar]
  166. European Medicines Agency. Hydroxyethyl-Starch Solutions (HES) No Longer to be Used in Patients with Sepsis or Burn Injuries or in Critically Ill Patients. Amsterdam, Netherlands: EMA; 2018. [Google Scholar]
  167. Navickis RJ, Haynes GR, Wilkes MM. Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: A meta-analysis of randomized trials. J Thorac Cardiovasc Surg. 2012;144:223–30. [CrossRef] [PubMed] [Google Scholar]
  168. Jacob M, Fellahi JL, Chappell D, et al. . The impact of hydroxyethyl starches in cardiac surgery: A meta-analysis. Crit Care. 2014;18:656. [CrossRef] [PubMed] [Google Scholar]
  169. Magder S, Potter BJ, Varennes BD, et al. . Fluids after cardiac surgery: A pilot study of the use of colloids versus crystalloids. Crit Care Med. 2010;38:2117–24. [CrossRef] [PubMed] [Google Scholar]
  170. Schramko A, Suojaranta-Ylinen R, Kuitunen A, et al. . Hydroxyethylstarch and gelatin solutions impair blood coagulation after cardiac surgery: A prospective randomized trial. Br J Anaesth. 2010;104:691–7. [CrossRef] [PubMed] [Google Scholar]
  171. Winterhalter M, Malinski P, Danzeisen O, et al. . Prospective observational study for perioperative volume replacement with 6% HES 130/0,42, 4% gelatin and 6% HES 200/0,5 in cardiac surgery. Eur J Med Res. 2010;15:383–9. [CrossRef] [PubMed] [Google Scholar]
  172. Myburgh JA, Finfer S, Bellomo R, et al. . Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012;367:1901–11. [CrossRef] [PubMed] [Google Scholar]
  173. Perner A, Haase N, Guttormsen AB, et al. . Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med. 2012;367:124–34. [CrossRef] [PubMed] [Google Scholar]
  174. Vives M, Callejas R, Duque P, et al. . Modern hydroxyethyl starch and acute kidney injury after cardiac surgery: A prospective multicentre cohort. Br J Anaesth. 2016;117:458–63. [CrossRef] [PubMed] [Google Scholar]
  175. Alavi SM, Ahmadi BB, Baharestani B, et al. . Comparison of the effects of gelatin, Ringer’s solution and a modern hydroxyl ethyl starch solution after coronary artery bypass graft surgery. Cardiovasc J Afr. 2012;23:428–31. [CrossRef] [PubMed] [Google Scholar]
  176. Datzmann T, Hoenicka M, Reinelt H, et al. . Influence of 6% hydroxyethyl starch 130/0.4 versus crystalloid solution on structural renal damage markers after coronary artery bypass grafting: A post hoc subgroup analysis of a prospective trial. J Cardiothorac Vasc Anesth. 2018;32:205–11. [CrossRef] [PubMed] [Google Scholar]
  177. Momeni M, Nkoy Ena L, Van Dyck M, et al. . The dose of hydroxyethyl starch 6% 130/0.4 for fluid therapy and the incidence of acute kidney injury after cardiac surgery: A retrospective matched study. PLoS One. 2017;12:e0186403. [CrossRef] [PubMed] [Google Scholar]
  178. Huang D, Chen C, Ming Y, et al. . Risk of massive blood product requirement in cardiac surgery: a large retrospective study from 2 heart centers. Medicine. 2019;98:e14219. [CrossRef] [PubMed] [Google Scholar]
  179. Tsukinaga A, Maeda T, Takaki S, et al. . Relationship between fresh frozen plasma to packed red blood cell transfusion ratio and mortality in cardiovascular surgery. J Anesth. 2018;32:539–46. [CrossRef] [PubMed] [Google Scholar]
  180. Tran A, Matar M, Lampron J, et al. . Early identification of patients requiring massive transfusion, embolization or hemostatic surgery for traumatic hemorrhage: A systematic review and meta-analysis. J Trauma Acute Care Surg. 2018;84:505–16. [CrossRef] [PubMed] [Google Scholar]
  181. Sikorski RA, Rizkalla NA, Yang WW, et al. . Autologous blood salvage in the era of patient blood management. Vox Sang. 2017;112:499–510. [CrossRef] [PubMed] [Google Scholar]
  182. Klein AA, Nashef SA, Sharples L, et al. . A randomized controlled trial of cell salvage in routine cardiac surgery. Anesth Analg. 2008;107:1487–95. [CrossRef] [PubMed] [Google Scholar]
  183. Vonk AB, Meesters MI, Garnier RP, et al. . Intraoperative cell salvage is associated with reduced postoperative blood loss and transfusion requirements in cardiac surgery: A cohort study. Transfusion. 2013;53:2782–9. [CrossRef] [PubMed] [Google Scholar]
  184. Paparella D, Whitlock R. Safety of salvaged blood and risk of coagulopathy in cardiac surgery. Semin Thromb Hemost. 2016;42:166–71. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.